ArticleBMJ open2025

Tremelimumab plus durvalumab versus sorafenib in first-line treatment of unresectable hepatocellular carcinoma: a cost-effectiveness analysis from the US payer perspective.

Shuqiao Cheng et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.